Shionogi & Co. said Tuesday it has applied to Taiwanese authorities for emergency use approval for its oral coronavirus drug, Xocova.
Shionogi & Co.'s oral COVID-19 drug Xocova. (Photo courtesy of Shionogi & Co.)(Kyodo)
The move marks the second time the Japanese pharmaceutical company has sought overseas authorization for the drug following its application to South Korean authorities in January. It has also been in talks with other countries, including the United States and China.
Japan's health ministry granted emergency approval for the drug in November. An estimated 37,000 patients had taken it by mid-March, the company said.
Related coverage:
Daiichi Sankyo seeks approval for Japan's 1st home-grown mRNA vaccine
Japan gives emergency approval to Shionogi's oral COVID-19 drug
